<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Par9">In the first temporal segment of the study (April 1, 2021 to November 30, 2021), when the Delta variant of COVID-19 was prevalent, vaccination against COVID-19 was associated with reduced rates of intracranial hemorrhage [7 days: 3.6% vs 7.0%; HR&#8201;=&#8201;0.52; 95% CI&#8201;=&#8201;0.37&#8211;0.73 and 30 days: 4.0% vs 7.7%; HR&#8201;=&#8201;0.51; 95% CI&#8201;=&#8201;0.37&#8211;0.71], venous thromboembolism [7 days: 3.2% vs 9.4%; HR&#8201;=&#8201;0.33; 95% CI&#8201;=&#8201;0.23&#8211;0.48 and 30 days: 4.0% vs 10.7%; HR&#8201;=&#8201;0.36; 95% CI&#8201;=&#8201;0.26&#8211;0.50] and acute myocardial infarction [7 days: 4.3% vs 8.5%; HR&#8201;=&#8201;0.50; 95% CI&#8201;=&#8201;0.36&#8211;0.70 and 30 days: 4.9% vs 9.2%; HR&#8201;=&#8201;0.52; 95% CI&#8201;=&#8201;0.38&#8211;0.71] (Table <xref rid="Tab3" ref-type="table">3</xref>). There was no association with reduced mortality in the vaccinated cohort.<table-wrap id="Tab3"><label>Table 3</label><caption><p>Seven- and thirty-day outcomes in propensity-matched COVID-19-associated stroke cases at two different timepoints</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th colspan="3">Part 1: April 1, 2021 to November 30, 3021 (Delta variant period)</th><th colspan="3">Part 2: December 01, 2021 to September 30, 2022 (Omicron variant period)</th></tr><tr><th/><th>Vaccinated <italic>N</italic>&#8201;=&#8201;1543 Events / Subjects (% Risk)</th><th>Unvaccinated <italic>N</italic>&#8201;=&#8201;1543 Events / Subjects (% Risk)</th><th>HR (95% CI), P value, log rank test</th><th>Vaccinated <italic>N</italic>&#8201;=&#8201;2083 Events / Subjects (% Risk)</th><th>Unvaccinated <italic>N</italic>&#8201;=&#8201;2083 Events / Subjects (% Risk)</th><th>HR (95% CI) P value, log rank test</th></tr></thead><tbody><tr><td colspan="7"><bold>7 days outcomes</bold></td></tr><tr><td>&#8195;All-cause mortality</td><td>42 / 1543 (2.7%)</td><td>56 / 1543 (3.6%)</td><td>0.74 (0.50, 1.10)</td><td>81 / 2083 (3.9%)</td><td>102 / 2083 (4.9%)</td><td>0.78 (0.59, 1.05)</td></tr><tr><td>&#8195;Intracranial hemorrhage*</td><td>51 / 1399 (3.6%)</td><td>97 / 1390 (7.0%)</td><td>0.52 (0.37, 0.73)</td><td>86 / 1917 (4.5%)</td><td>109 / 1923 (5.7%)</td><td>0.79 (0.59, 1.04)</td></tr><tr><td>&#8195;Venous thromboembolic events*</td><td>38 / 1205 (3.2%)</td><td>114 / 1219 (9.4%)</td><td>0.33 (0.23, 0.48)</td><td>59 / 1631 (3.6%)</td><td>136 / 1695 (8.0%)</td><td>0.44 (0.33, 0.60)</td></tr><tr><td>&#8195;Acute myocardial infarction*</td><td>53 / 1225 (4.3%)</td><td>107 / 1264 (8.5%)</td><td>0.50 (0.36, 0.70)</td><td>67 / 1684 (4.0%)</td><td>132 / 1719 (7.7%)</td><td>0.51 (0.38, 0.69)</td></tr><tr><td>&#8195;G-tube placement*</td><td>10 / 1514 (0.7%)</td><td>13 / 1512 (0.9%)</td><td>0.61 (0.25, 1.47)</td><td>10 / 2041 (0.5%)</td><td>14 / 2063 (0.7%)</td><td>0.43 (0.16, 1.11)</td></tr><tr><td>&#8195;Mechanical ventilation*</td><td>55 / 1425 (3.9%)</td><td>73 / 1455 (5.0%)</td><td>0.76 (0.54, 1.08)</td><td>102 / 1932 (5.3%)</td><td>92 / 1976 (4.7%)</td><td>1.13 (0.85, 1.50)</td></tr><tr><td colspan="7"><bold>30-days outcomes</bold></td></tr><tr><td>&#8195;All-cause mortality</td><td>110 / 1543 (7.1%)</td><td>122 / 1543 (7.9%)</td><td>0.87 (0.67, 1.12)</td><td>195 / 2083 (9.4%)</td><td>201 / 2083 (9.7%)</td><td>0.93 (0.77, 1.14)</td></tr><tr><td>&#8195;Intracranial hemorrhage*</td><td>56 / 1399 (4.0%)</td><td>107 / 1390 (7.7%)</td><td>0.51 (0.37, 0.71)</td><td>96 / 1917 (5.0%)</td><td>115 / 1923 (6.0%)</td><td>0.83 (0.63, 1.09)</td></tr><tr><td>&#8195;Venous thromboembolic events*</td><td>48 / 1205 (4.0%)</td><td>131 / 1219 (10.7%)</td><td>0.36 (0.26, 0.50)</td><td>80 / 1631 (4.9%)</td><td>156 / 1695 (9.2%)</td><td>0.52 (0.40, 0.68)</td></tr><tr><td>&#8195;Acute myocardial infarction*</td><td>60 / 1225 (4.9%)</td><td>116 / 1264 (9.2%)</td><td>0.52 (0.38, 0.71)</td><td>77 / 1684 (4.6%)</td><td>141 / 1719 (8.2%)</td><td>0.55 (0.41, 0.72)</td></tr><tr><td>&#8195;G-tube placement*</td><td>29 / 1514 (1.9%)</td><td>33 / 1512 (2.2%)</td><td>0.85 (0.52, 1.40)</td><td>28 / 2041 (1.4%)</td><td>43 / 2063 (2.1%)</td><td>0.63 (0.39, 1.01)</td></tr><tr><td>&#8195;Mechanical ventilation*</td><td>71 / 1425 (5.0%)</td><td>93 / 1455 (6.4%)</td><td>0.77 (0.56, 1.04)</td><td>116 / 1932 (6.0%)</td><td>100 / 1976 (5.1%)</td><td>1.18 (0.90, 1.54)</td></tr></tbody></table><table-wrap-foot><p><sup>*</sup>The denominator is less than the total number listed in the column header due to exclusion of patients who had an outcome of interest before the index stroke. New outcome of interest that occurred only after the index stroke were calculated.</p></table-wrap-foot></table-wrap></p>